Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating whether an AI-powered large language model can help doctors improve the diagnosis of rare or difficult-to-diagnose diseases. This trial compares the use of AI-assisted diagnostic support with standard clinical care to see if it improves diagnostic accuracy, speeds up diagnosis, and affects health-economic outcomes for patients with suspected rare diseases. The study is a multicenter randomized controlled trial involving physicians and patients across various hospitals. Participants are randomly assigned to one of two groups one where doctors use the AI system during patient consultations to organize clinical information, analyze cases, and suggest possible diagnoses, and another group where doctors follow standard diagnostic procedures without AI assistance. Use of other generative AI tools is not allowed in either group. The trial also includes an economic evaluation to track healthcare resources and costs related to the diagnostic process. Participants will have a first consultation with their physician, during which various measures are recorded, including the duration of the consultation and experiences reported by both patients and doctors. Outcomes such as correct diagnostic yield, diagnostic accuracy, time to diagnosis, and appropriate genetic testing recommendations will be evaluated over approximately eight weeks following the initial visit. The study uses blinded independent experts to assess the diagnostic outcomes, and participants are expected to complete structured follow-up during this period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of inhaled Peginterferon alpha-2b at two different doses combined with supportive care for children aged 1 to 6 years who have common hand, foot, and mouth disease HFMD. This multicenter clinical trial aims to better understand treatment options for this illness by comparing two dose levels of the medicine delivered by nebulization. The study is sponsored by Zhengzhou Childrens Hospital in China and plans to enroll 90 participants. Participants will be randomly assigned to one of two groups receiving either 45 mcg or 90 mcg doses of nebulized Peginterferon alpha-2b on Day 1 and Day 3, alongside standard supportive care. The study includes a 3-day screening period followed by a 5-7 day inpatient treatment phase during which the investigational treatments are administered. The trial focuses on monitoring responses to these treatments while participants remain hospitalized. During participation, children will be closely monitored for the resolution of fever, skin rash, oral ulcers, and feeding difficulties over the first week. Researchers will collect data on the time it takes for these symptoms to improve or resolve. They will also assess safety by tracking any serious complications such as pulmonary edema or myocarditis. The total participation involves screening, inpatient observation, and follow-up to measure treatment outcomes and safety.